Equillium ( (EQ) ) has released its Q4 earnings. Here is a breakdown of the information Equillium presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, leveraging its expertise in immunobiology. In its latest earnings report, Equillium shared financial results for the fourth quarter and full year 2024, alongside significant clinical developments. The company highlighted the Phase 3 EQUATOR study results for itolizumab in treating acute graft-versus-host disease, which showed promising long-term outcomes despite not meeting primary short-term endpoints. Financially, Equillium reported a decrease in quarterly revenue to $4.4 million from $9.2 million in the previous year, though annual revenue increased to $41.1 million. The company also noted a reduction in R&D and G&A expenses, contributing to a narrower net loss for the year. Looking ahead, Equillium anticipates feedback from the FDA regarding potential accelerated approval for itolizumab, which could significantly impact its strategic direction and financial health.